We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Merck has launched its LANEXO Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed for labs. The new laboratory informatics solution is said
Roche has obtained the US Food and Drug Administration (FDA) breakthrough device designation for its Elecsys GALAD score, a serum biomarker-based model that predicts hepatocellular carcinoma in chronic
US-based healthcare services provider Thermo Fisher Scientific has agreed to acquire molecular diagnostic technologies firm Qiagen for approximately $11.5bn. QIAGEN is a provider of life science and molecular
Roche subsidiary Genentech has obtained the US Food and Drug Administration (FDA) breakthrough therapy designation for its Esbriet (pirfenidone) to treat unclassifiable interstitial lung disease (uILD) in adult
US-based biopharmaceutical company Gilead Sciences has agreed to acquire clinical-stage immuno-oncology firm Forty Seven for approximately $4.9bn in cash. The transaction is expected to be completed, subject to
Japanese pharmaceutical firm Takeda has agreed to sell its portfolio of select non-core products in Latin America to Brazil-based Hypera Pharma for $825m. Takeda said that the portfolio
US-based clinical-stage biopharmaceutical firm Altimmune has completed the design and synthesis of the single-dose, intranasal vaccine against COVID-19, the disease caused by the SARS-CoV-2 virus. Altimmune said that
US-based FUJIFILM Diosynth Biotechnologies (FDB) has started the planned capacity expansion of its ‘Flexible Biomanufacturing Facility’ located at College Station, Texas. FDB is a cGMP contract development and
US-based biotechnology firm Biogen has signed a global licensing agreement with genomic medicine company Sangamo Therapeutics to develop and commercialise therapies addressing several neurological diseases. Under the terms
The European Medicines Agency (EMA) has accepted GlaxoSmithKline (GSK)’s regulatory submission seeking an additional indication for Trelegy Ellipta to treat asthma, along with Type II Variation (T2V) Zejula